162 related articles for article (PubMed ID: 8319398)
1. In-111 CYT-103 immunoscintigraphy in the imaging of ovarian carcinoma.
Neal CE; Baker MR; Hilgers RD; Fanning J; Burke RC; Snodgrass J; Cull RD
Clin Nucl Med; 1993 Jun; 18(6):472-6. PubMed ID: 8319398
[TBL] [Abstract][Full Text] [Related]
2. Clinical assessment of 111In-CYT-103 immunoscintigraphy in ovarian cancer.
Surwit EA; Childers JM; Krag DN; Katterhagen JG; Gallion HH; Waggoner S; Mann WJ
Gynecol Oncol; 1993 Mar; 48(3):285-92. PubMed ID: 8462896
[TBL] [Abstract][Full Text] [Related]
3. Ovarian cancer: comparison of findings with perfluorocarbon-enhanced MR imaging, In-111-CYT-103 immunoscintigraphy, and CT.
Low RN; Carter WD; Saleh F; Sigeti JS
Radiology; 1995 May; 195(2):391-400. PubMed ID: 7724757
[TBL] [Abstract][Full Text] [Related]
4. Immunoscintigraphy of colorectal carcinoma utilizing 111In-labeled monoclonal antibody conjugate CYT-103.
Neal CE; Swan TL; Baker MR; Ellis RL; Katterhagen JG
Gastrointest Radiol; 1991; 16(3):251-5. PubMed ID: 1879645
[TBL] [Abstract][Full Text] [Related]
5. Results of immunoscintigraphy using a cocktail of radiolabeled monoclonal antibodies in the detection of colorectal cancer.
Volpe CM; Abdel-Nabi HH; Kulaylat MN; Doerr RJ
Ann Surg Oncol; 1998 Sep; 5(6):489-94. PubMed ID: 9754756
[TBL] [Abstract][Full Text] [Related]
6. The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma. A preliminary report.
Method MW; Serafini AN; Averette HE; Rodriguez M; Penalver MA; Sevin BU
Cancer; 1996 Jun; 77(11):2286-93. PubMed ID: 8635097
[TBL] [Abstract][Full Text] [Related]
7. Multicenter clinical trial of 111In-CYT-103 in patients with ovarian cancer.
Gallup DG
Targeted Diagn Ther; 1992; 6():111-24. PubMed ID: 1576342
[No Abstract] [Full Text] [Related]
8. In-111 CYT-103 monoclonal antibody imaging in patients with suspected recurrent colorectal cancer.
Doerr RJ; Herrera L; Abdel-Nabi H
Cancer; 1993 Jun; 71(12 Suppl):4241-7. PubMed ID: 8508386
[TBL] [Abstract][Full Text] [Related]
9. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT.
Collier BD; Abdel-Nabi H; Doerr RJ; Harwood SJ; Olsen J; Kaplan EH; Winzelberg GG; Grossman SJ; Krag DN; Mitchell EP
Radiology; 1992 Oct; 185(1):179-86. PubMed ID: 1523304
[TBL] [Abstract][Full Text] [Related]
10. Use of the radiolabeled murine monoclonal antibody, 111In-CYT-103, in the management of colon cancer.
Petersen BM; Bass BL; Bates HR; Chandeysson PL; Harmon JW
Am J Surg; 1993 Jan; 165(1):137-42; discussion 142-3. PubMed ID: 8418688
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature.
Pinkas L; Robins PD; Forstrom LA; Mahoney DW; Mullan BP
Nucl Med Commun; 1999 Aug; 20(8):689-96. PubMed ID: 10451876
[TBL] [Abstract][Full Text] [Related]
12. 111In-CYT-103 scanning in recurrent colorectal cancer--does it affect standard management?
Dominguez JM; Wolff BG; Nelson H; Forstrom LA; Mullan BP
Dis Colon Rectum; 1996 May; 39(5):514-9. PubMed ID: 8620800
[TBL] [Abstract][Full Text] [Related]
13. Immunoscintigraphy using 111InCyt103 prior to second look laparotomy in ovarian cancer. A pilot study.
Hempling RE; Piver MS; Baker TR; Bakshi S; Gilani SS
Am J Clin Oncol; 1994 Aug; 17(4):331-4. PubMed ID: 8048395
[TBL] [Abstract][Full Text] [Related]
14. In-111 CYT-103 immunoscintigraphy of isolated splenic metastasis from ovarian carcinoma.
Nguyen BD; Regan F
Clin Nucl Med; 1997 Apr; 22(4):256-7. PubMed ID: 9099487
[No Abstract] [Full Text] [Related]
15. Clinical immunoscintigraphy of recurrent ovarian cancer with indium 111-labeled B72.3 monoclonal antibody.
Krag DN; Ford P; Smith L; Taylor M; Schneider PD; Bushberg JT; Goodnight JE
Arch Surg; 1993 Jul; 128(7):819-23. PubMed ID: 8317965
[TBL] [Abstract][Full Text] [Related]
16. Role of In-111 labeled CYT-103 immunoscintigraphy in the evaluation of patients with recurrent colorectal carcinoma.
Markowitz A; Saleemi K; Freeman LM
Clin Nucl Med; 1993 Aug; 18(8):685-700. PubMed ID: 8403703
[TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of In-111 satumomab pendetide immunoscintigraphy. An aid to visual interpretation of images in patients with suspected carcinomatosis.
Neal CE; Johnson DL; Cornwell VL; Markwell S
Clin Nucl Med; 1996 Aug; 21(8):638-42. PubMed ID: 8853918
[TBL] [Abstract][Full Text] [Related]
18. Challenges in immunoscintigraphy of ovarian cancer.
Kim EE; Kasi LP
Gynecol Oncol; 1993 Mar; 48(3):283-4. PubMed ID: 8462895
[No Abstract] [Full Text] [Related]
19. Multicenter clinical trials of monoclonal antibody B72.3-GYK-DTPA 111In (111In-CYT-103; OncoScint CR103) in patients with colorectal carcinoma.
Abdel-Nabi HH; Doerr RJ
Targeted Diagn Ther; 1992; 6():73-88. PubMed ID: 1576351
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunodetection of colorectal carcinoma.
Artiko V; Obradovic V; Davidovic B; Petrovic N; Petrovic M; Krivokapic Z; Kecmanovic D; Pesko P; Djukic V; Milosavljevic T; Adanja G; Vlajkovic M
Hepatogastroenterology; 2003; 50(52):1029-31. PubMed ID: 12845972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
